JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
Solace Therapeutics today released data from a trial of its Vesair bladder control device, touting that the study met its endpoints “with statistical significance.” The Framingham, Mass.-based company’s Vesair bladder control device is comprised of a compressible air-filled balloon which acts as a “shock-abosrber” to slow rapid chanes in pressure that can cause Stress Urinary […]
Globus Medical filed for an initial public offering yesterday, saying it’s planning a reverse split of its existing stock just before the IPO launches.
The Audubon, Pa.-based orthopedic device maker, which ran afoul of the FDA last month, said it hopes to trade under the "GMED" ticker on the New York Stock Exchange.
Solace Therapeutics capped a big week with a win at the MassMEDIC 11th Annual Medtech Investors Conference, landing the first MedTech Ignite 10k Innovative Technology Competition award.
The Framingham, Mass.-based medical device maker won CE Mark approval in the European Union Oct. 1 for its intravesical system to treat female stress urinary incontinence.
Solace Therapeutics Inc. won CE Mark approval in the European Union for its intravesical system to treat female stress urinary incontinence.
The Framingham, Mass.-based medical device maker said its device is a small, quarter-sized balloon that floats inside the bladder. Inserted via catheter during an out-patient procedure, the balloon is designed to relieve the pressure fluctuations within the bladder that lead to incontinence.